TW200817410A
(en)
|
2006-08-07 |
2008-04-16 |
Incyte Corp |
Triazolotriazines as kinase inhibitors
|
US7563797B2
(en)
|
2006-08-28 |
2009-07-21 |
Forest Laboratories Holding Limited |
Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
|
ME02372B
(en)
*
|
2006-11-22 |
2016-06-20 |
Incyte Holdings Corp |
Imidazotriazines and imidazopyrimidines as kinase inhibitors
|
EP2025674A1
(en)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
|
WO2009032754A2
(en)
*
|
2007-08-31 |
2009-03-12 |
Kalypsys, Inc. |
Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
|
TWI472529B
(en)
|
2008-05-21 |
2015-02-11 |
Incyte Corp |
Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
|
RU2011123647A
(en)
|
2008-11-10 |
2012-12-20 |
Вертекс Фармасьютикалз Инкорпорейтед |
COMPOUNDS USEFUL AS ATR KINASE INHIBITORS
|
AU2009326148B2
(en)
|
2008-12-11 |
2014-05-08 |
Respivert Limited |
p38 MAP kinase inhibitors
|
CA3013000C
(en)
|
2008-12-19 |
2022-12-13 |
Vertex Pharmaceuticals Incorporated |
Pyrazine derivatives useful as inhibitors of atr kinase
|
WO2010079241A1
(en)
*
|
2009-01-12 |
2010-07-15 |
Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion |
Use of antagonists and/or inverse agonists of cb1 receptors for the preparation of drugs that increase motor neuron excitability
|
CA2756759C
(en)
|
2009-04-16 |
2017-11-07 |
Joaquin Pastor Fernandez |
Imidazopyrazines for use as kinase inhibitors
|
GB0921730D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Method of treatment
|
GB0921731D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Theraputic uses
|
EP2531509B1
(en)
|
2010-02-03 |
2016-10-05 |
Incyte Holdings Corporation |
Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
|
CA2798760A1
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
2-aminopyridine derivatives useful as inhibitors of atr kinase
|
EP2569287B1
(en)
|
2010-05-12 |
2014-07-09 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
WO2011143419A1
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
Pyrazines useful as inhibitors of atr kinase
|
EP2569286B1
(en)
|
2010-05-12 |
2014-08-20 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
EP2568984A1
(en)
|
2010-05-12 |
2013-03-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
SG185524A1
(en)
|
2010-05-12 |
2012-12-28 |
Vertex Pharma |
Compounds useful as inhibitors of atr kinase
|
EP2585468A1
(en)
|
2010-06-23 |
2013-05-01 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
|
EP2444084A1
(en)
|
2010-10-21 |
2012-04-25 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Use of PI3K inibitors for the treatment of obesity
|
WO2012120054A1
(en)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
EP2683699B1
(en)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120052A1
(en)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
KR101326557B1
(en)
*
|
2011-03-31 |
2013-11-08 |
주식회사종근당 |
Benzamide derivatives as cannabinoid cb1 receptor antagonists
|
JP2014510151A
(en)
|
2011-04-05 |
2014-04-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Aminopyrazine compounds useful as ATR kinase (TRAKINASE) inhibitors
|
EP2723746A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
JP2014522818A
(en)
|
2011-06-22 |
2014-09-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Compounds useful as ATR kinase inhibitors
|
US8822469B2
(en)
|
2011-06-22 |
2014-09-02 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
|
EP2751088B1
(en)
|
2011-09-30 |
2016-04-13 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
CA2850564A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
WO2013049726A2
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Processes for making compounds useful as inhibitors of atr kinase
|
CA2850491C
(en)
|
2011-09-30 |
2020-10-27 |
Vertex Pharmaceuticals Incorporated |
Treating pancreatic cancer and non-small cell lung cancer with atr inhibiors
|
US8853217B2
(en)
|
2011-09-30 |
2014-10-07 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
WO2013071088A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
JP2015502925A
(en)
|
2011-11-09 |
2015-01-29 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Pyrazine compounds useful as inhibitors of ATR kinase
|
EP2776429A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
US8841450B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
WO2013071090A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
US9260435B2
(en)
|
2012-01-10 |
2016-02-16 |
Bayer Pharma Aktiengesellschaft |
Substituted imidazopyrazines as Akt kinase inhibitors
|
MX358818B
(en)
|
2012-04-05 |
2018-09-05 |
Vertex Pharma |
Compounds useful as inhibitors of atr kinase and combination therapies thereof.
|
WO2014055756A1
(en)
|
2012-10-04 |
2014-04-10 |
Vertex Pharmaceuticals Incorporated |
Method for measuring atr inhibition mediated increases in dna damage
|
US8912198B2
(en)
|
2012-10-16 |
2014-12-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
ME03042B
(en)
|
2012-11-19 |
2018-10-20 |
Novartis Ag |
Compounds and compositions for the treatment of parasitic diseases
|
ES2946360T3
(en)
|
2012-12-07 |
2023-07-17 |
Vertex Pharma |
Pyrazolo[1,5-a]pyrimidines useful as ATR kinase inhibitors for the treatment of cancer diseases
|
CN103012284A
(en)
*
|
2012-12-26 |
2013-04-03 |
无锡捷化医药科技有限公司 |
Preparation method of 2-amino-5-bromopyrimidine compound
|
CN104936953B
(en)
|
2013-01-23 |
2017-03-08 |
阿斯利康(瑞典)有限公司 |
Compound
|
WO2014143240A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
RU2687276C2
(en)
|
2013-12-06 |
2019-05-13 |
Вертекс Фармасьютикалз Инкорпорейтед |
Compounds suitable for use as atr kinase inhibitors
|
GB201321736D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
LT3152212T
(en)
|
2014-06-05 |
2020-05-11 |
Vertex Pharmaceuticals Inc. |
Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
|
SG11201610500WA
(en)
|
2014-06-17 |
2017-01-27 |
Vertex Pharma |
Method for treating cancer using a combination of chk1 and atr inhibitors
|
CA3000684A1
(en)
|
2015-09-30 |
2017-04-06 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of dna damaging agents and atr inhibitors
|
US20170107216A1
(en)
|
2015-10-19 |
2017-04-20 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
AU2016358100B2
(en)
|
2015-11-19 |
2021-05-27 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
DK3394033T3
(en)
|
2015-12-22 |
2021-01-04 |
Incyte Corp |
HETEROCYCLIC COMPOUNDS AS IMMUNE MODULATORS
|
MA44860A
(en)
|
2016-05-06 |
2019-03-13 |
Incyte Holdings Corp |
HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
|
US20170342060A1
(en)
|
2016-05-26 |
2017-11-30 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
BR112018076534A2
(en)
|
2016-06-20 |
2019-04-02 |
Incyte Corporation |
heterocyclic compounds as immunomodulators
|
WO2018013430A2
(en)
|
2016-07-12 |
2018-01-18 |
Arisan Therapeutics Inc. |
Heterocyclic compounds for the treatment of arenavirus infection
|
ES2930092T3
(en)
|
2016-07-14 |
2022-12-07 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
US10000500B2
(en)
|
2016-07-28 |
2018-06-19 |
Promega Corporation |
Coelenterazine analogues
|
CN106317043B
(en)
*
|
2016-08-19 |
2018-11-02 |
成都理工大学 |
A kind of 2 agonist of Cannabined receptor
|
CN106317059B
(en)
*
|
2016-08-19 |
2018-10-12 |
成都理工大学 |
A kind of 2 (CB2) agonist of Cannabined receptor
|
EP3504198B1
(en)
|
2016-08-29 |
2023-01-25 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
EP3558985B1
(en)
|
2016-12-22 |
2022-09-07 |
Incyte Corporation |
Benzooxazole derivatives as immunomodulators
|
MY197501A
(en)
|
2016-12-22 |
2023-06-19 |
Incyte Corp |
Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
|
MA47120A
(en)
|
2016-12-22 |
2021-04-28 |
Incyte Corp |
PYRIDINE DERIVATIVES USED AS IMMUNOMODULATORS
|
EP3558989B1
(en)
|
2016-12-22 |
2021-04-14 |
Incyte Corporation |
Triazolo[1,5-a]pyridine derivatives as immunomodulators
|
CR20200520A
(en)
|
2018-03-30 |
2021-03-09 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
EP3790877B1
(en)
|
2018-05-11 |
2023-03-01 |
Incyte Corporation |
Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
|
GB201811695D0
(en)
|
2018-07-17 |
2018-08-29 |
Salvensis |
Compounds for use in the treatment of fascioliasis
|
TW202115059A
(en)
|
2019-08-09 |
2021-04-16 |
美商英塞特公司 |
Salts of a pd-1/pd-l1 inhibitor
|
TW202126652A
(en)
|
2019-09-30 |
2021-07-16 |
美商英塞特公司 |
Pyrido[3,2-d]pyrimidine compounds as immunomodulators
|
AU2020385113A1
(en)
|
2019-11-11 |
2022-05-19 |
Incyte Corporation |
Salts and crystalline forms of a PD-1/PD-L1 inhibitor
|
CA3200844A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
|
TW202233615A
(en)
|
2020-11-06 |
2022-09-01 |
美商英塞特公司 |
Crystalline form of a pd-1/pd-l1 inhibitor
|
WO2022099018A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Process of preparing a pd-1/pd-l1 inhibitor
|
US20240101563A1
(en)
*
|
2022-07-28 |
2024-03-28 |
Ac Immune Sa |
Novel compounds
|